>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Hanmi Financial (HAFC) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $25.50
    • NextEra Energy Partners (NEP) upgraded to Neutral from Underweight at JP Morgan; tgt lowered to $22
    • Regions Fincl (RF) upgraded to Buy from Hold at Deutsche Bank; tgt raised to $26
    • Steris (STE) upgraded to Overweight from Neutral at Piper Sandler; tgt raised to $260
    • Tesla (TSLA) upgraded to Outperform from Neutral at KGI Securities
    • UP Fintech (TIGR) upgraded to Buy from Hold at China Renaissance
  • Downgrades:
    • ATI Inc. (ATI) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
    • Avery Dennison (AVY) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $210
    • Constellium (CSTM) downgraded to Hold from Buy at Deutsche Bank; tgt lowered to $12
    • Dyne Therapeutics (DYN) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $35
    • Helix Energy (HLX) downgraded to Neutral from Buy at BTIG Research
    • Howmet Aerospace (HWM) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
    • ICON plc (ICLR) downgraded to Neutral from Outperform at Robert W. Baird; tgt $340
    • MAG Silver (MAG) downgraded to Neutral from Buy at ROTH MKM; tgt raised to $17.50
    • OUTFRONT Media (OUT) downgraded to Peer Perform from Outperform at Wolfe Research
    • Seres Therapeutics (MCRB) downgraded to Underweight from Neutral at JP Morgan
    • U.S. Bancorp (USB) downgraded to Hold from Buy at Deutsche Bank; tgt $51
    • Verizon (VZ) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
    • WillScot Mobile Mini (WSC) downgraded to Neutral from Outperform at Robert W. Baird; tgt $42
  • Others:
    • Avalo Therapeutics (AVTX) initiated with a Neutral at H.C. Wainwright
    • Bit Digital (BTBT) initiated with a Buy at B. Riley Securities; tgt $6
    • Blueprint Medicines (BPMC) initiated with a Neutral at UBS; tgt $88
    • California Resources Corp (CRC) initiated with a Buy at Jefferies; tgt $64
    • CG Oncology (CGON) initiated with a Buy at UBS; tgt $60
    • Cullinan Therapeutics (CGEM) initiated with a Buy at UBS; tgt $30
    • Gen Digital (GEN) initiated with an Overweight at Wells Fargo; tgt $35
    • IDEAYA Biosciences (IDYA) initiated with a Buy at UBS; tgt $50
    • Immunocore (IMCR) initiated with a Sell at UBS; tgt $24
    • Iovance Biotherapeutics (IOVA) initiated with a Buy at UBS; tgt $17
    • Janux Therapeutics (JANX) initiated with a Buy at UBS; tgt $69
    • Keros Therapeutics (KROS) initiated with an Overweight at Cantor Fitzgerald
    • Kura Oncology (KURA) initiated with a Buy at UBS; tgt $27
    • Lufax (LU) resumed with a Hold at Jefferies; tgt $3.20
    • Merus (MRUS) initiated with a Buy at UBS; tgt $72
    • Nurix Therapeutics (NRIX) initiated with a Buy at UBS; tgt $35
    • Nuvalent (NUVL) initiated with a Neutral at UBS; tgt $100
    • Perspective Therapeutics (CATX) initiated with a Buy at UBS; tgt $20
    • Q32 Bio (QTTB) initiated with a Strong Buy at Raymond James; tgt $90
    • Retail Opportunity Investments (ROIC) resumed with an Underperform at BofA Securities; tgt $14
    • Sempra Energy (SRE) initiated with a Buy at Jefferies; tgt $98
    • Sirius XM (SIRI) resumed with an Underperform at BofA Securities; tgt $23
    • Syndax Pharmaceuticals (SNDX) initiated with a Buy at UBS; tgt $37
    • Tenax Therapeutics (TENX) initiated with an Outperform at Leerink Partners; tgt $16